ArticleCancer medicine2025
Characteristics and Outcomes of Second Primary Multiple Myeloma in Adult Cancer Survivors: A Population-Based Cohort Study.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThis study aimed to investigate characteristics and outcomes of second primary multiple myeloma (2-MM) stratified by prior primary malignancies (PPMs), and further explore the effect of PPM treatment modalities on multiple myeloma (MM) prognosis in the United States (US) population.
methodsThe retrospective study was analyzed based on MM patients in the Surveillance, Epidemiology, and End Results (SEER) database (2000-2021). Patients with 2-MM, defined as MM diagnosed ≥ 6 months after a PPM, were stratified into 25 subgroups based on PPM categories. Univariable and multivariable competing risk regression models were constructed to estimate MM-specific mortality. The Kaplan-Meier method and a multivariable Cox regression model were conducted to analyze all-cause mortality.
resultWe identified 74,932 patients with first primary multiple myeloma (1-MM) and 6465 patients with 2-MM. Compared to the 1-MM cohort, the 2-MM cohort exhibited a higher proportion of males, older age at diagnosis, and greater representation of the White race. The multivariable analysis demonstrated a reduced risk of MM-specific mortality in 2-MM against 1-MM. PPMs of soft tissue (including heart), melanoma of the skin, corpus uteri, prostate, kidney and renal pelvis, and lymphoma, showed protective effects on MM-specific mortality in 2-MM. Notably, many PPMs that developed into 2-MM exhibited elevated all-cause mortality risks in multivariable analysis. Additionally, chemotherapy for prior lymphoma was associated with an increased all-cause mortality risk in 2-MM patients, whereas, radiotherapy for prior breast cancer and surgery for prior prostate cancer were linked to a decreased risk.
conclusionCompared to 1-MM, 2-MM exhibited distinct characteristics and survival outcomes in adults, which were associated with PPM types and their treatment modalities. These findings provide critical insights for risk stratification and survivorship care in US adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.